Introduction
============

In the last two decades, the demand for functional foods and nutraceuticals has increased significantly in China. In China, individuals are beginning to pay more attention to their own health, and self-health care awareness is increasing. Therefore, in order to satisfy consumer needs, bioactive peptides from various foods are isolated by enzymatic hydrolysis and their functional activities are being investigated ([@b1-mmr-16-05-6697],[@b2-mmr-16-05-6697]). Bioactive peptide hydrolysates have gained increasing attention due to their physiologic effects on cardiovascular, gastrointestinal, nervous and immune systems ([@b3-mmr-16-05-6697]). The hydrolysates of numerous marine organisms, such as *Pardachirus marmoratus (P. marmoratus;* also known as the Red Sea Moses sole), have been demonstrated to possess significant antitumor activities ([@b4-mmr-16-05-6697]). Cancer is a disease of worldwide importance. Its incidence in developed countries is increasing, and cancer is the second most common cause of mortality ([@b5-mmr-16-05-6697]). In 2017, 1.69 million new cancer cases and 59,000 mortalities from cancer are projected to occur in the United States ([@b6-mmr-16-05-6697]). Therefore, there is an urgent requirement for the development of novel tumor-targeted therapies that specifically and effectively target tumor cells with low toxicity to normal tissues ([@b7-mmr-16-05-6697]--[@b9-mmr-16-05-6697]).

Prostate cancer is one of the world\'s most commonly diagnosed cancer, and is second to lung cancer as the leading cause of cancer-associated mortality in men ([@b6-mmr-16-05-6697]). In China, prostate cancer is currently the most common malignancy diagnosed in men, and is one of the ten most common cancers in urban areas ([@b10-mmr-16-05-6697]). Prostate cancer has the seventh highest incidence rate, and it is the tenth leading cause of cancer-associated mortality in males residing in urban areas, with a mortality rate of 3.67/100,000 males in 2010 ([@b11-mmr-16-05-6697]). During the early development of prostate carcinomas, the growth of prostate epithelial cells is androgen-dependent ([@b5-mmr-16-05-6697]). Therefore, hormone therapy is a primary method used to treat patients with prostate cancer. However, a proportion of tumor cells become androgen-independent ([@b12-mmr-16-05-6697]). Despite the improved efficacy of chemotherapy for the majority of cancer types over the last 30 years, the highly toxic effects of chemotherapeutic drugs, such as doxorubicin, have lead to a significant reduction in the quality of life of patients, which remains a formidable problem in clinical medicine ([@b13-mmr-16-05-6697]). Therefore, the discovery and development of novel potent anticancer agents with minimal toxicity are in high demand.

In the present study, hydrolysates derived from the enzymatic hydrolysis of the common marine organism, *Sinonovacula constricta (S. constricta)*, were evaluated as a source of antitumor peptides. *S. constricta* is a commercially important bivalve that is used as food in China. In order to optimize its use for human consumption, and potentially gain higher value-added advantages, the authors of the present study focused on the utilization of *S. constricta* to obtain bioactive peptides and investigate their antitumor effects, with the aim of increasing the survival rates from cancer and enhancing the quality of life of patients. A number of bioactive peptides derived from marine organisms, such as the marine sponge, *Jaspis jonhstoni, P. marmoratus*, and somocystinamide A isolated from a *Lyngbya majuscula/Schizothrix* spp. marine cyanobacteria, have been demonstrated to possess significant antitumor activities ([@b4-mmr-16-05-6697],[@b14-mmr-16-05-6697]--[@b16-mmr-16-05-6697]). For instance, jasplakinolide (also known as jaspamide), a cyclic depsipeptide, inhibited human Jurkat T cell growth by inducing apoptosis ([@b17-mmr-16-05-6697]). In addition, a short peptide isolated from the heated products of half-fin anchovy (*Setipinna taty*) peptide hydrolysates demonstrates antiproliferative activities against human PC-3 prostate cancer cells ([@b18-mmr-16-05-6697]). However, the bioactivities of hydrolysates derived from *S. constricta*, particularly with regards to its nutraceutical and pharmaceutical applications, have not yet been reported. Therefore, the aim of the present study was to determine whether *S. constricta* might be a useful source of antitumor peptides obtained by enzymatic hydrolysis. Enzymatic hydrolysis was used to generate complex mixtures of similar molecular weight (MW) fractions, which were subsequently subject to ultrafiltration, and high-performance liquid chromatography (HPLC) was employed to obtain purified peptide fractions. The acquired peptides were evaluated for their antiproliferative properties using the colorimetric MTT assay. Peptides confirmed to possess potent antiproliferative activities were selected for identification of their amino acid composition and sequence. In addition, the mechanisms underlying the antiproliferative effects of identified peptides were investigated further.

Materials and methods
=====================

### Materials

A total of 10 kg *S. constricta* were obtained from Beimen market in Zhoushan City, (Zhejiang, China). The muscles were rapidly separated, and stored at −80°C. Trypsin, pepsin, papain, alcalase, acetonitrile and trifluoroacetic acid (TFA) were purchased from YTHX Biotechnology Co., Ltd. (Beijing, China; [www.ythxbio.com](www.ythxbio.com)). The MTT assay reagent was purchased from Beyotime Institute of Biotechnology (Nanjing, China). All additional reagents used were of analytical grade. Hormone-dependent DU-145 and PC-3 cell lines were obtained from the China Cell Bank of the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). The annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) Apoptosis Detection and cell cycle staining kits were obtained from YTHX Biotechnology Co., Ltd.

### Cell culture conditions

DU-145 and PC-3 cells were cultured in Ham\'s F-12 medium supplemented with 10% fetal calf serum (FBS) (both Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% penicillin/streptomycin (10,000 U/ml penicillin G sodium and 10,000 mg/ml streptomycin sulfate) (Thermo Fisher Scientific, Inc.). Cells were cultured in an incubator at 37°C and 5% CO~2~ in a humidified atmosphere.

### Preparation of S. constricta hydrolysates (SCH)

Hydrolysis of *S. constricta* muscles was performed using trypsin, pepsin, papain and alcalase enzymes. *S. constricta* meal (500 g) was homogenized using a tissue homogenizer and suspended in distilled water at a ratio of 1:2 (m/m). The homogenate was adjusted to the optimum conditions for digestion with trypsin, pepsin, papain or alcalase using 1.0 N NaOH or 1.0 N HCI. The *S. constricta* homogenate was hydrolyzed using the four proteases at a concentration of 3% (m/m, enzyme/substrate), and at the pH and temperatures listed in [Table I](#tI-mmr-16-05-6697){ref-type="table"}. The enzymatic hydrolysate mixtures were incubated for 5 h at 37°C in a thermostatic water bath. The enzymatic reactions were inactivated by heating the mixtures for 15 min at 100°C. The mixture was centrifuged at 4,472 × g for 15 min at 4°C, and the soluble fraction was collected. The resulting SCH were lyophilized and stored at −80°C for downstream analysis.

### Membrane fractionation

The SCH was isolated using the Amicon 8400 Stirred Ultrafiltration Unit (EMD Millipore, Billerica, MA, USA) with MW thresholds of 3, 5 and 8 KDa. Briefly, the freeze-dried SCH samples were diluted in distilled water (1:3) and the following fractions were collected: SCH-I, MW ≥8 kDa; SCH-II, 5≤ MW \<8 kDa; SCH-III, 3≤ MW \<5 kDa; and SCH-IV, MW \<3 kDa. The SCH group was the unfractionated sample. All SCH fractions were lyophilized and their antitumor activities were determined using DU-145 and PC-3 cells.

### Gel filtration chromatography

The SCH fraction (500 mg/ml) exhibiting the highest antitumor activity following ultrafiltration, was further separated using Sephadex G-25 gel filtration media (YTHX Biotechnology Co., Ltd) and a gel filtration column (2.5×80 cm; 75--180 µm), eluted with distilled water at a flow rate of 1 ml/min at room temperature. Each fraction was detected at 280 nm. The SCH-IV fraction was further sub-fractionated into 5 groups, using G-25, by molecular weight. G-25 may be used to fractionate the molecules between 1 and 5 kDa. Bioactive fractions were collected by a computerized automatic collector (Shanghai Qingpu Huxi Instrument Factory, Shanghai, China) and lyophilized for an antitumor activity assay.

### HPLC

The sample obtained from the Sephadex G-25 gel which demonstrated the highest antitumor activity was further purified by reverse-phase (RP)-HPLC using an Agilent 1260 Infinity system (Agilent Technologies, Inc., Santa Clara, USA) and a Zorbax SB-C18 column (4.6×250 mm; 5 µm; Agilent Technologies, Inc.) and the column temperature was 30°C. The mixture of acetonitrile (A) and 0.06% TFA (B) was used as mobile phase in linear gradient mode (5--30% of A for 0--50 min; 30--75% of A for 50--80 min), with a flowrate of 0.8 ml/min. Elution peaks were detected at 280 nm, and were collected for determination of antitumor activity. The amino acid sequences of purified peptides were then determined.

### Amino acid sequence analysis and determination of molecular mass

A total of 200 µg protein was mixed with 250 µl rehydration solution and rehydrated for 14 h using an IPGphor (GE Healthcare, Beijing, China). The isoelectric focusing was achieved with four steps, then carried out by two-dimensional gel electrophoresis ([@b19-mmr-16-05-6697]). Following pretreatment, the samples (50 pmol/20 µl) were directly sequenced using a Shimadzu PPSQ-31A automated gas phase protein sequencer (Shimadzu Corporation, Kyoto, Japan). Briefly, samples were dissolved in 20 µl CH~3~CN (37%; v/v) solution and applied to TFA-treated glass fiber membranes pre-treated with polybrene (Shimadzu Corporation). Data were recorded using Shimadzu PPSQ version 31A software (Shimadzu Corporation). An accurate molecular mass of SCH-P9 and SCH-P10 peptides was determined using an LTQ FT Ultra mass spectrometer (Thermo Fisher Scientific, Inc.). The ^1^H nuclear magnetic resonance (NMR) and 13C NMR spectra were recorded in d-dimethyl sulfoxide (DMSO) on a Bruker AV-400 spectrometer (Bruker Corporation, Billerica, MA, USA) at working frequencies 400 and 100 MHz. Chemical shifts are expressed in parts per million (δ) values and coupling constants (J) in Hz. High resolution electrospray ionization mass spectrometry (HRESI-MS) were measured on the LTQ FT Ultra instrument. The above procedure was performed by Wuhan Moon Biosciences Co., Ltd. (Wuhan, China).

### MTT assay

The effects of SCH on cell viability were determined using a colorimetric MTT assay. Briefly, DU-145 and PC-3 cells were seeded at a density of 1×10^4^ cells/well in 96-well plates, and incubated for 24 h to allow cells to adhere to the surface of the plates in a humidified atmosphere, in a 5% CO~2~ incubator at 37°C (Forma; Thermo Fisher Scientific, Inc.). The DU-145 and PC-3 cells were then treated with SCH at 1, 5, 10 mg/ml for 24 h. DU-145 and PC-3 control cells were treated with F-12 culture medium. Cell viability was detected by adding MTT reagent. A total of 20 µl MTT solution was added to each well for an additional 4--5 h at 37°C. Following the addition of the DMSO solution (150 µl) to each well to dissolve the formazan crystals, the optical density (OD) was read at a wavelength of 450 nm using a Model 680 Microplate Reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Three independent experiments were performed, and the cell inhibitory rate (A value) was determined using the following equation: Inhibition (%) = \[(OD~control~-OD~treated~)/(OD~control~-OD~blank~) × 100\].

### Cell cycle analysis

Cell cycle analysis and measurement of cellular DNA content were performed following synchronization. Synchronization was achieved by incubating DU-145 and PC-3 cells in 0.5% FBS F-12 medium for 48 h in a humidified atmosphere with 5% CO~2~ at 37°C. DU-145 and PC-3 cells were seeded in six-well plates (1×10^5^ cells/well) and allowed to adhere overnight. DU-145 cells were treated with SCH-P9 (1.21 mg/ml), SCH-P10 (1.41 mg/ml) and fluorouracil (5-FU; 2.02 µg/ml) for 24 h. PC-3 cells were treated with SCH-P9 (1.09 mg/ml), SCH-P10 (0.91 mg/ml) and 5-FU (2.14 µg/ml) for 24 h. For cell cycle analysis, cells were first collected by trypsinization, fixed in 70% ethanol, washed in cold phosphate-buffered saline (PBS; pH 7.4) and then stained with PI solution (50 µg/ml PI, 100 µg/ml RNase and 0.1% Triton X-100 in PBS) for 30 min in the dark at room temperature. The DNA content of DU-145 and PC-3 cells was analyzed using a Guava easyCyte Flow Cytometer (EMD Millipore). Histograms showing the population of cells in each cell cycle phase based on DNA content were constructed using GuavaSoft software (version, 4.20; EMD Millipore). A total of three independent experiments were performed, and the results are presented as the mean ± standard deviation.

### Cell apoptosis analysis

Cell apoptosis detection was performed using fluorescence-activated cell sorting (FACS) analysis. The exposure of phosphatidylserine on the extracellular side of the cell membrane was quantified by annexin V-FITC/PI staining. DU-145 and PC-3 cells were seeded in six-well plates (1×10^5^ cells/well). DU-145 cells were treated with SCH-P9 (1.21 mg/ml), SCH-P10 (1.41 mg/ml) or 5-FU (2.02 µg/ml) for 24 h. PC-3 cells were treated with SCH-P9 (1.09 mg/ml), SCH-P10 (0.91 mg/ml) or 5-FU (2.14 µg/ml) for 24 h. The cells were collected by trypsinization. Following centrifugation at 213 × g at 4°C for 5 min, cell pellets were washed twice with cold PBS. Cells were then incubated with 5 µl annexin V-FITC and 10 µl PI (Shanghai BestBio, Shanghai, China), according to the manufacturer\'s protocol, at room temperature for 15 min in the dark. Binding buffer (400 µl; 1X) was subsequently added to each tube and the cells were immediately analyzed using a Guava easyCyte Flow Cytometer (EMD Millipore). The data were analyzed using GuavaSoft software (version, 4.20; EMD Millipore).

### Statistical analysis

Data are presented as the mean ± standard deviation of at least three independent experiments. Data were analyzed by one-way repeated measures analysis of variance with Tukey test using SPSS software (version 16; SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Preparation of S. constricta enzymatic hydrolysates

SCHs were produced by incubating the organisms with trypsin, pepsin, papain or alcalase enzymes under optimal conditions ([Table I](#tI-mmr-16-05-6697){ref-type="table"}). The antitumor activities of the hydrolysates were assessed using an MTT assay and the results are shown in [Table II](#tII-mmr-16-05-6697){ref-type="table"}. Out of all hydrolysates, the pepsin hydrolysate exhibited the highest antiproliferative activity against DU-145 and PC-3 human prostate cancer cell lines ([Table II](#tII-mmr-16-05-6697){ref-type="table"}). Therefore, the pepsin hydrolysate was selected for further study.

### Ultrafiltration of SCH

SCHs were fractionated by MW using an ultrafiltration membrane bioreactor system, with MW thresholds of 8, 5 and 3 kDa. Therefore, four different fractions were obtained and divided into SCH-I, (MW ≥8 kDa), SCH-II (5≤ MW \<8 kDa), SCH-III (3≤ MW \<5 kDa) and SCH-IV, (MW \<3 kDa) groups. The SCH group was treated with the unfractionated sample. SCH, SCH-I, SCH-II, SCH-III and SCH-IV inhibited the growth of DU-145 and PC-3 cells in a dose-dependent manner ([Fig. 1](#f1-mmr-16-05-6697){ref-type="fig"}). In addition, SCH-IV exhibited the highest antiproliferative activity among all of the fractions ([Fig. 1](#f1-mmr-16-05-6697){ref-type="fig"}). Therefore, SCH-IV was selected for further purification by gel filtration chromatography.

### Gel filtration chromatography of the SCH-IV fraction

As shown in [Fig. 2A](#f2-mmr-16-05-6697){ref-type="fig"}, SCH-IV was further separated into five fractions, termed SCH-IV-1, SCH-IV-2, SCH-IV-3, SCH-IV-4 and SCH-IV-5. Out of all fractions examined, SCH-IV-5 demonstrated the greatest inhibitory effect on the growth of DU-145 and PC-3 cells ([Fig. 2B](#f2-mmr-16-05-6697){ref-type="fig"}). Therefore, SCH-IV-5 was selected for further purification by HPLC to isolate and characterize the peptides responsible for the observed antiproliferative effects.

### Isolation of peptides from SCH-IV-5 by RP-HPLC

SCH-IV-5 was further purified by RP-HPLC. As shown in [Fig. 3](#f3-mmr-16-05-6697){ref-type="fig"}, SCH-IV-5 was separated into 12 fractions, termed SCH-P1, SCH-P2, SCH-P3, SCH-P4, SCH-P5, SCH-P6, SCH-P7, SCH-P8, SCH-P9, SCH-P10, SCH-P11 and SCH-P12, and their antiproliferative effects on DU-145 and PC-3 cells were investigated. The antiproliferative activities of SCH-P9 and SCH-P10 peptides were greater when compared with the remaining 10 peptides. Therefore, SCH-P9 and SCH-P10 were considered to be the peptides exhibiting the greatest antitumor activity, and their sequences were identified as Leu-Pro-Gly-Pro and Asp-Tyr-Val-Pro, respectively ([Fig. 4](#f4-mmr-16-05-6697){ref-type="fig"}). The purity of SCH-P9 and SCH-P10 were 95.99 and 96.99%, and the yields were 5.79 and 8.92%, respectively.

### Growth inhibition rate of DU-145 and PC-3 cells following treatment with SCH-P9 and SCH-P10

DU-145 and PC-3 cells were exposed to 0.1, 0.5, 1.0, 5.0, and 10 mg/ml SCH-P9 or SCH-P10 for 6, 12 or 24 h. At all doses examined, SCH-P9 and SCH-P10 effectively inhibited the growth of DU-145 and PC-3 cells at 6, 12, and 24 h ([Fig. 5A and B](#f5-mmr-16-05-6697){ref-type="fig"}). A time- and dose-dependent increase in the growth inhibition rate of DU-145 and PC-3 cells treated with SCH-P9 and SCH-P10 was observed ([Fig. 5A and B](#f5-mmr-16-05-6697){ref-type="fig"}). The maximal inhibitory concentration (IC~50~) of SCH-P9 on DU-145 cells was 12.66, 5.45 and 1.21 mg/ml at 6, 12 and 24 h, respectively. The IC~50~ of SCH-P10 on DU-145 cells was 11.28, 5.49 and 1.41 mg/ml at 6, 12 and 24 h, respectively. The IC~50~ of SCH-P9 on PC-3 cells was 12.09, 5.96 and 1.09 mg/ml at 6, 12 and 24 h, respectively. The IC~50~ of SCH-P10 on PC-3 cells was 10.94, 5.12 and 0.91 mg/ml at 6, 12 and 24 h, respectively. Of particular note, SCH-P9 and SCH-P10 did not inhibit the growth of DU-145 and PC-3 cells to a greater extent when compared with 5-FU under a similar growth inhibition rate ([Fig. 5C](#f5-mmr-16-05-6697){ref-type="fig"}).

### Effect of SCH-P9 and SCH-P10 on the cell cycle distribution of DU-145 and PC-3 cells

In order to investigate the mechanisms responsible for SCH-P9- and SCH-P10-mediated cell growth inhibition, the cell cycle distribution of DU-145 and PC-3 cells were evaluated by flow cytometry. A representative example indicating the effect of SCH-P9 and SCH-P10 treatment for 24 h on cell cycle phase distribution is shown in [Fig. 6](#f6-mmr-16-05-6697){ref-type="fig"}. When compared with the untreated cells, treatment with SCH-P10 was associated with an increase in the number of DU-145 cells in the sub-G1 phase, together with a concomitant increase in the proportion of cells in the G~0~/G~1~ phase, and a decrease in the number of cells in S and G~2~/M phases ([Fig. 6](#f6-mmr-16-05-6697){ref-type="fig"}). However, there were no significant changes in the cell cycle distribution of DU-145 cells following treatment with SCH-P9. When compared with untreated controls, SCH-P9 reduced the number of PC-3 cells in subG~1~ and G~0~/G~1~ phases, whereas an increased number were observed in the G~2~/M phase; however, these alterations did not reach statistical significance ([Fig. 6](#f6-mmr-16-05-6697){ref-type="fig"}). SCH-P10 treatment significantly reduced the number of PC-3 cells in G~2~/M phase, and significantly increased the number in G~0~/G~1~ phase when compared with untreated controls ([Fig. 6](#f6-mmr-16-05-6697){ref-type="fig"}).

### SCH-P9 and SCH-P10 induced apoptosis of DU-145 and PC-3 cells

In order to determine whether the observed alterations in prostate cancer cell cycle distributions following treatment with SCH-P9 and SCH-P10 were due to increased levels of apoptosis, treated DU-145, and PC-3 cells were stained with annexin V-FITC/PI and analyzed by flow cytometry. As shown in [Fig. 7](#f7-mmr-16-05-6697){ref-type="fig"}, treatment of DU-145 and PC-3 cells with SCH-P9 and SCH-P10 for 24 h was associated with a significant increase in early apoptosis rates when compared with untreated control cells. The percentage of DU-145 cells in early apoptosis following treatment with 2.02 µg/ml 5-FU was 26.71%, which was significantly lower than the percentage of DU-145 cells in early apoptosis following treatment with 1.41 mg/ml SCH-P10 ([Fig. 7](#f7-mmr-16-05-6697){ref-type="fig"}). However, the percentage of DU-145 cells in late apoptosis following treatment with 2.02 µg/ml 5-FU was 40.95%, which was higher than the number of cells in late apoptosis following treatment with 1.41 mg/ml SCH-P10. Similar alterations in the number of PC-3 cells in early and late apoptosis following treatment with 5-FU and SCH-P10 were observed ([Fig. 7](#f7-mmr-16-05-6697){ref-type="fig"}).

Discussion
==========

Bioactive peptides obtained by enzymatic hydrolysis are gaining increased attention due to their unique amino acid compositions, and they may hold promise for a wide range of therapeutic applications ([@b20-mmr-16-05-6697]). Bioactive peptides may reduce disease risk and promote human health ([@b20-mmr-16-05-6697]). Peptides that induce apoptosis of tumor cells are considered to be effective anticancer agents.

Anticancer peptides derived from marine sources and their potential use as alternative anticancer treatments has been well established. For instance, a novel peptide derived from *Ruditapes philippinarum*, with an N-terminal amino acid sequence identified as Ala-Val-Leu-Val-Asp-Lys-Gln-Cys-Pro-Asp, effectively induces apoptosis of prostate cancer cells ([@b21-mmr-16-05-6697]). In addition, Ala-Phe-Asn-Ile-His-Asn-Arg-Asn-Leu-Leu, a decapeptide derived from the pepsin hydrolysates of the *Mytilus coruscus* shellfish, has been demonstrated to exhibit anticancer properties ([@b22-mmr-16-05-6697]).

In the present study, a low MW peptide derived from the hydrolysate of *S. constricta* was observed to exhibit the strongest inhibitory effects on the growth of DU-145 and PC-3 cells, and was therefore purified further. A number of previous studies have demonstrated that bioactive peptides are primarily low MW peptides ([@b23-mmr-16-05-6697]--[@b25-mmr-16-05-6697]). The sepia ink oligopeptide, a tripeptide extracted from Sepia ink *(Sepia esculenta)*, induces apoptosis of prostate cancer cell lines via caspase-3 activation and elevation of the Bcl-2 like protein 4/B-cell lymphoma-2 (Bcl-2) ratio ([@b26-mmr-16-05-6697]).

In the current study, SCH-P9 and SCH-P10 fractions inhibited the growth of PC-3 and DU-145 cells to a greater extent when compared with the other SCH fractions. The peptide size and composition of the amino acids in protein hydrolysates serve crucial roles in their cell inhibitory activity ([@b27-mmr-16-05-6697]). The N-terminal amino acid sequence and molecular mass of SCH-P9 and SCH-P10 were determined using a Shimadzu PPSQ-31A automated gas phase sequencer followed by a Thermo Fisher Scientific LTQ FT Ultra mass spectrometer. The sequences of SCH-P9 and SCH-P10 were identified as Leu-Pro-Gly-Pro (MW, 382.46 Da) and Asp-Tyr-Val-Pro (MW, 492.53 Da), respectively. The SCH-P9 and SCH-P10 peptides were effective against the growth of PC-3 and DU-145 cells in a time and dose-dependent manner. Lower MW peptides demonstrate greater molecular mobility and diffusivity when compared with higher MW peptides, which contributes to enhanced interactions with cancer cell components and therefore increases anticancer activities ([@b28-mmr-16-05-6697]).

A number of peptides obtained from marine animal species have been demonstrated to exert strong antitumor activities, including didemnin B, keenamide A, kahalalide F, jasplakinolide, aurilide and theopedirn B ([@b17-mmr-16-05-6697]). These antitumor compounds possess tumor-targeting abilities, with lower toxicity in normal tissues. The properties of these anticancer peptides make them promising therapeutic agents, as functional food ingredients or antitumor drugs that may be used for cancer prevention and/or treatment. Therefore, investigating anticancer peptides, such as SCH-P9 and SCH-P10, may be important for the development of novel cancer prevention and treatment strategies. Future studies investigating the molecular structure and antitumor mechanisms of SCH-P9 and SCH-P10 may promote the emergence of tetrapeptides as novel functional food ingredients or antitumor drugs.

In recent years, an increasing number of marine anticancer peptides have been identified. For instance, jasplakinolide, which is a cyclic depsipeptide with a 15-carbon macrocyclic ring, was isolated from marine sponge *Jaspis splendens* ([@b29-mmr-16-05-6697]). This peptide induced apoptosis HCT-116 and HeLa cells by activating caspase-3 and decreasing Bcl-2 protein expression ([@b29-mmr-16-05-6697]). Analogs of jasplakinolide, such as jasplakinolide B, C, and V, isolated from *Jaspis. splendens* have demonstrated anticancer activities in NCI60 cells ([@b29-mmr-16-05-6697]). It has been reported that dolastatin 10, isolated from the marine mollusk *Dolabella auricularia*, is a linear pentapeptide that inhibits the proliferation of murine L1210 leukemia cells ([@b12-mmr-16-05-6697],[@b17-mmr-16-05-6697],[@b30-mmr-16-05-6697]). In addition, the growth-inhibiting effects of this peptide were associated with induction of apoptosis via increasing p53 and decreasing Bcl-2 expression levels. Similarly, SCH-P9 and SCH-P10 were demonstrated to serve a role in increasing apoptosis of prostate cancer cells. An increase in PI and annexin V staining in DU-145 and PC-3 cells was observed following treatment with SCH-P9 and SCH-P10 for 24 h, which indicates that SCH-P9 and SCH-P10 induces apoptosis of prostate cancer cells.

The acquisition of novel anticancer peptides from marine sources has gained significant attention due to potential therapeutic applications. Foodstuffs that improve the state of health and/or reduce the risk of disease are defined as functional foods ([@b31-mmr-16-05-6697]). Functional foods with added health benefits, such as anticancer effects, are currently of major interest to consumers. In the present study, SCH-P9 and SCH-P10 demonstrated antitumor effects and possessed apoptosis-inducing activities. *S. constricta* may therefore present a source of functional food, and its derivatives, SCH-P9 and SCH-P10, may be useful as anticancer therapies.

In conclusion, the results of the current study present the purification and characterization of two novel anticancer peptides derived from the peptide hydrolysates of *S. constricta*. The two peptides, SCH-P9 and SCH-P10, were identified as Leu-Pro-Gly-Pro (MW, 382.46 Da) and Asp-Tyr-Val-Pro (MW, 492.53 Da), respectively. SCH-P9 and SCH-P10 inhibited the growth of DU-145 and PC-3 cells in a dose- and time-dependent manner. These results indicate that SCH-P9 and SCH-P10 present a potential source of functional food, which may promote the emergence of tetrapeptides as novel functional food ingredients or antitumor drugs.
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![(A) Gel filtration chromatography of the SCH-IV fraction using a Sephadex G-15 column. (B) The effect of increasing concentrations of SCH-IV on the growth of DU-145 and PC-3 cells. The results are expressed as the mean ± standard deviation, and each experiment was performed in triplicate. \*P\<0.05 vs. 1 mg/ml SCH-IV, ^\#^P\<0.05 vs. 5 mg/ml SCH-IV, ^\$^P\<0.05 vs. 10 mg/ml SCH-IV. SCH, *Sinonovacula constricta* hydrolysates.](mmr-16-05-6697-g01){#f2-mmr-16-05-6697}

![(A) A chromatogram showing the 12 fractions of SCH-IV-5 separated by reverse-phase-high-performance liquid chromatography using a Zorbax SB-C18 column. (B) The effect of increasing concentrations of SCH-IV-5 fractions on the growth of DU-145 and PC-3 prostate cancer cells. \*P\<0.05 vs. 1 mg/ml SCH-IV-5, ^\#^P\<0.05 vs. 5 mg/ml SCH-IV-5, ^\$^P\<0.05 vs. 10 mg/ml SCH-IV-5. SCH, *Sinonovacula constricta* hydrolysates.](mmr-16-05-6697-g02){#f3-mmr-16-05-6697}

![Mass spectroscopy analysis of (A) SCH-P9 and (B) SCH-P10 fractions. SCH-P9 and SCH-P10 sequences were identified as Leu-Pro-Gly-Pro and Asp-Tyr-Val-Pro, respectively, and their molecular structures are shown. SCH, *Sinonovacula constricta* hydrolysates.](mmr-16-05-6697-g03){#f4-mmr-16-05-6697}

![Effect of increasing concentrations of (A) SCH-P9, (B) SCH-P10 and (C) 5-FU on the growth of DU-145 and PC-3 cells for 6, 12 and 24 h. The percentage cell growth inhibition is presented relative to untreated controls (0% inhibition). An MTT assay was used to measure cell growth following treatment with SCH fractions and 5-FU. The results are expressed as the mean ± standard deviation, and each experiment was performed in triplicate. \*P\<0.05 vs. untreated controls. SCH, *Sinonovacula constricta* hydrolysates; 5-FU, fluorouracil.](mmr-16-05-6697-g04){#f5-mmr-16-05-6697}

![(A) Cell cycle distribution profiles and of DU-145 and PC-3 cells following treatment with SCH-P9, SCH-P10 or 5-FU for 24 h. (B) Stacked column graphs showing the percentage of DU-145 and PC-3 cells in each cell cycle phase following treatment with SCH-P9, SCH-P10 or 5-FU for 24 h. Data are expressed as the mean ± standard deviation (n=3). \*P\<0.05 vs. untreated group. SCH, *Sinonovacula constricta* hydrolysates; 5-FU, fluorouracil.](mmr-16-05-6697-g05){#f6-mmr-16-05-6697}

![Apoptosis of DU-145 and PC-3 cells following treatment with SCH-P9, SCH-P10 or 5-FU for 24 h as determined by annexin-FITC/PI staining and FACS analysis. Plots from one of three independent FACS assays are shown. \*P\<0.05 vs. untreated group in late apoptosis; ^\#^P\<0.05 vs. untreated group in early apoptosis. SCH, *Sinonovacula constricta* hydrolysates; 5-FU, fluorouracil; FITC, fluorescein isothiocyanate; PI, propidium iodide; FACS, fluorescence-activated cell sorting.](mmr-16-05-6697-g06){#f7-mmr-16-05-6697}

###### 

Optimum conditions for the enzymatic digestion of *Sinonovacula constricta* using four proteinases.

             Optimum conditions   
  ---------- -------------------- ----
  Trypsin    7.5                  37
  Pepsin     2.0                  37
  Papain     6.0                  37
  Alcalase   8.0                  37

###### 

Effect of different enzymatic *Sinonovacula constricta* hydrolysates on the percentage growth inhibition of human prostate cancer cell lines.

  Enzymatic lysate   DU-145 (%)   PC-3 (%)
  ------------------ ------------ -----------
  Trypsin            33.67±2.3    48.23±6.3
  Pepsin             86.24±3.5    88.21±7.3
  Papain             45.26±5.4    44.75±1.4
  Alcalase           69.32±5.6    67.28±7.1
